AFSTYLA® (rFVIII-Single Chain) – FDA approval

Melbourne, Australia — 26/05/2016

CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [Antihaemophilic Factor (Recombinant), Single Chain], CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with haemophilia A.

Afstyla

AFSTYLA is indicated in adults and children with haemophilia A for routine prophylaxis to prevent or reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and the perioperative management of bleeding. AFSTYLA is expected to be available in the US early this US summer.

"For 100 years, CSL has focused on researching and developing innovative therapies that meet the treatment challenges patients face,” said Dr. Andrew Cuthbertson, Chief Scientific Officer and Director of R&D, CSL Limited. "The approval of AFSTYLA, an innovative and effective haemophilia A therapy, further demonstrates CSL’s dedication to developing and delivering novel therapies that have the potential to improve patients’ lives. We are very excited to add this treatment to our industry-leading portfolio of coagulation therapies and look forward to the positive impact AFSTYLA can have on patients with haemophilia A.”

About Haemophilia A
Primarily affecting males, haemophilia A is a congenital bleeding disorder characterized by deficient or defective factor VIII. People with haemophilia A may experience prolonged or spontaneous bleeding, especially into the muscles, joints or internal organs. According to the US Centers for Disease Control and Prevention (CDC), the condition affects approximately 1 in 6,000 male births.

About AFSTYLA
AFSTYLA (also known as rVIII-Single Chain) for haemophilia A is CSL Behring’s recombinant single-chain factor VIII specifically designed for greater molecular stability and longer duration of action. AFSTYLA uses a covalent bond that forms one structural entity, a single polypeptide-chain, to improve the stability of factor VIII and provide longer-lasting factor VIII activity.

AFSTYLA is the first and only single-chain product for haemophilia A that is specifically designed for long-lasting protection from bleeds with twice-weekly dosing available. Regulatory agencies in Europe, Switzerland and Australia are currently reviewing CSL Behring’s license applications for AFSTYLA.



Download this release: 
PDF icon AFSTYLA® (rFVIII-Single Chain) – FDA approval  (0.5Mb)


For further information, please contact:

Investors:
  Mark Dehring
  Head of Investor Relations
  CSL Limited
  Phone: +613 9389 3407
  Email: mark.dehring@csl.com.au
Media:
  Sharon McHale
  Head of Public Affairs
  CSL Limited
  Mobile: +61 409 978 314
  Email: sharon.mchale@csl.com.au

 

© 2017 CSL Limited